These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39238648)

  • 1. Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study.
    Strunz PP; Risser LM; Englbrecht M; Witte T; Froehlich M; Schmalzing M; Gernert M; Hueper S; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Welcker M; Kleinert S
    Front Immunol; 2024; 15():1445680. PubMed ID: 39238648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
    Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
    Front Immunol; 2024; 15():1395968. PubMed ID: 38846940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".
    Skaarup L; Ingrid E; Sepriano A; Nikiphorou E; Østgård R; Lauper K; Grosse-Michaelis I; Kloppenburg M; Glintborg B; Liew DFL; Kragstrup TW
    Drug Saf; 2024 Nov; 47(11):1075-1093. PubMed ID: 39012469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis.
    Wollenberg A; Thyssen JP; Bieber T; Chan G; Kerkmann U
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2041-2046. PubMed ID: 37319107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Hernández-Cruz B; Otero-Varela L; Freire-González M; Busquets-Pérez N; García González AJ; Moreno-Ramos M; Blanco-Madrigal JM; Manrique-Arija S; Perez-Pampin E; Ruiz-Montesino D; Sánchez-Alonso F; Sanchez-Piedra C; Castrejón I;
    Ann Rheum Dis; 2024 Aug; 83(9):1189-1199. PubMed ID: 38594056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
    Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed JAK Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross-Sectional Study.
    Janak JC; Ross RD; Brady BL; Palmer L; Howard JT; Baker JF
    Arthritis Care Res (Hoboken); 2024 Sep; 76(9):1287-1293. PubMed ID: 38682605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
    Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
    Rheumatol Int; 2024 Oct; 44(10):2057-2066. PubMed ID: 39136784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
    Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
    Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
    Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A
    Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
    Reddy V; Cohen S
    Curr Opin Rheumatol; 2021 May; 33(3):300-306. PubMed ID: 33767091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis.
    Chen YW; Chen HH; Huang WN; Chen JP; Chen YH; Chen YM
    Clin Rheumatol; 2024 Jan; 43(1):117-128. PubMed ID: 37658935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset.
    Ciciriello S; Littlejohn GO; Treuer T; Gibson KA; Haladyj E; Youssef P; Bird P; O'Sullivan C; Smith T; Deakin CT
    Clin Exp Rheumatol; 2024 Sep; 42(9):1763-1772. PubMed ID: 38757292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
    Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY
    Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
    Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
    Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
    Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry.
    Padula AS; Pappas DA; Fiore S; Blachley TS; Ford K; Emeanuru K; Kremer JM
    Arthritis Res Ther; 2022 Dec; 24(1):276. PubMed ID: 36544236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.
    Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
    Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
    Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.